Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

A large study spanning more than 40 years suggested that migraines in midlife were associated with a modest increase in the long-term risk of dementia. Adults with migraines in midlife were slightly ...

Something we have noticed from readers and clients recently is a greater awareness of lighting, and to a certain extent, switching. For many years, most clients were happy to have a lighting plan put ...

DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

Dear Dr. Roach: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

March 20 (Reuters) - EyePoint (EYPT.O), opens new tab filed a lawsuit on Friday accusing rival Ocular Therapeutix (OCUL.O), opens new tab of spreading false or misleading information about EyePoint ...

I’ve had the great thrill of seeing the northern lights, both from Alaska and Iceland. But that experience pales next to what I witnessed recently at my favorite coffee shop. I was there for my usual ...

The right lighting in a home office can boost productivity, sharpen focus and inspire creativity. But the wrong lighting can easily cause fatigue, eye strain and headaches. The key to getting it right ...

A migraine attack is not just a “bad headache”. Migraine is a debilitating neurological condition which can cause nausea, vomiting, and sensitivity to light or sound, in addition to severe headaches.

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...